二甲基-(1-苯基-环己基甲基)-胺 | 101355-47-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 二甲基-(1-苯基-环己基甲基)-胺
• 英文名称: dimethyl-(1-phenyl-cyclohexylmethyl)-amine
• 英文别名: Dimethyl-(1-phenyl-cyclohexylmethyl)-amin；N,N-dimethyl-(1-phenylcyclohexyl)methanamine；N,N-dimethyl-1-(1-phenylcyclohexyl)methanamine
• CAS: 101355-47-9
• 化学式: C₁₅H₂₃N
• 分子量: 217.354
• InChiKey: XQUUVZDIAMCEHA-UHFFFAOYSA-N

物化性质

• 沸点：
  138 °C(Press: 0.8 Torr)
• 密度：
  0.943±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-Phenyl-cyclohexylessigsaeurechlorid 在 sodium azide 、 水 作用下， 生成 二甲基-(1-苯基-环己基甲基)-胺
  参考文献：
  名称：

  Takahashi et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1958, vol. 78, p. 1,3

  摘要：

  DOI：

文献信息

• Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof
  申请人：Gruss Michael

  公开号：US20070032551A1

  公开（公告）日：2007-02-08

  Novel 3-[2-(dimethylamino)methyl-(cyclohex-1-yl)]-phenol fumarate compounds corresponding to formula I: and processes for preparing these compounds are provided. Pharmaceutical compositions including these compounds and methods of treating or alleviating pain with these compounds are also provided.

  新型3-[2-(二甲基氨基)甲基-(环己-1-基)]-酚富马酸盐化合物对应于式I： 提供了制备这些化合物的方法。还提供了包括这些化合物的药物组合物以及使用这些化合物治疗或缓解疼痛的方法。
• Cycloalkylamines as monoamine reuptake inhibitors
  申请人：Shao Liming

  公开号：US20070203111A1

  公开（公告）日：2007-08-30

  The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

  本发明涉及新型环己胺衍生物及其在中枢神经系统（CNS）疾病的治疗和/或预防中的应用，例如抑郁症、焦虑症、精神分裂症和睡眠障碍，以及它们的合成方法。本发明还涉及包含本发明化合物的制药组合物，以及抑制内源性单胺，如多巴胺、5-羟色胺和去甲肾上腺素从突触间隙中再摄取的方法和调节一个或多个单胺转运体的方法。
• Salt of Dimethylaminomethyl-Phenyl-Cyclohexane and Crystalline Forms Thereof
  申请人：GRUSS Michael

  公开号：US20110046230A1

  公开（公告）日：2011-02-24

  Novel 3-[2-(dimethylamino)methyl-(cyclohex-1-yl)]-phenol maleate compounds corresponding to formula I and processes for preparing these compounds are provided. Pharmaceutical compositions including these compounds and methods of treating or alleviating pain with these compounds are also provided.

  提供了符合公式I的新型3-[2-(二甲氨基)甲基-(环己基)]-酚马来酸盐化合物及制备这些化合物的方法。还提供了包括这些化合物的制药组合物以及使用这些化合物治疗或缓解疼痛的方法。
• CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS
  申请人：Shao Liming

  公开号：US20100190861A1

  公开（公告）日：2010-07-29

  The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

  本发明涉及新型环己基胺衍生物及其在治疗和/或预防中枢神经系统（CNS）疾病方面的应用，例如抑郁症，焦虑症，精神分裂症和睡眠障碍，以及它们的合成方法。本发明还涉及含有本发明化合物的制药组合物，以及抑制内源性单胺，如多巴胺，5-羟色胺和去甲肾上腺素从突触间隙中再摄取的方法，以及调节一个或多个单胺转运体的方法。
• Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor
  作者：Liming Shao、Michael C. Hewitt、Fengjiang Wang、Scott C. Malcolm、Jianguo Ma、John E. Campbell、Una C. Campbell、Sharon R. Engel、Nancy A. Spicer、Larry W. Hardy、Rudy Schreiber、Kerry L. Spear、Mark A. Varney

  DOI：10.1016/j.bmcl.2011.01.016

  日期：2011.3

  The current work discloses a novel cyclohexylarylamine chemotype with potent inhibition of the serotonin, norepinephrine, and dopamine transporters and potential for treatment of major depressive disorder. Optimized compounds 1 (SERT, NET, DAT, IC50 = 169, 85, 21 nM) and 42 (SERT, NET, DAT IC50 = 34, 295, 90 nM) were highly brain penetrant, active in vivo in the mouse tail suspension test at 30 mpk po and were not general motor stimulants. (C) 2011 Elsevier Ltd. All rights reserved.